Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors01:13

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors

706
Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
706
FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

111
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
111
Carrier-Mediated Transport01:06

Carrier-Mediated Transport

833
Carrier-mediated transport is a pivotal process in drug absorption, particularly for lipid-insoluble drugs, and encompasses facilitated diffusion and active transport. Facilitated diffusion allows drugs to move along their concentration gradient without energy expenditure, while active transport utilizes ATP to drive drug movement against this gradient.
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
833
Hepatic Drug Clearance: Role of Transporters01:14

Hepatic Drug Clearance: Role of Transporters

211
In the liver and bile canaliculi, influx and efflux transporters modification can influence intrinsic clearance. Transporters play a significant role in moving drugs within liver cells. Elaborate models, such as the Biopharmaceutical Classification System (BCS), are essential to relate transporters to drug disposition. This system categorizes drugs into four classes based on solubility and permeability, providing insights into elimination routes and the effects of transporters following oral...
211
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

96
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
96
Pharmacokinetics: Drug–Food and Drug–Viral Interactions01:26

Pharmacokinetics: Drug–Food and Drug–Viral Interactions

105
A drug interaction occurs when the concurrent use of another drug, food, or an external substance alters the pharmacological activity of a drug. This interaction can modify the action of the original drug, affecting its effectiveness and safety.Drug–food interactions are significant as they impact drug absorption, metabolism, and excretion. For example, grapefruit juice is a well-known disruptor of drug metabolism. It inhibits the cytochrome P450 3A4 enzyme, crucial for the metabolism of...
105

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Characteristic Correlation between Staphylococcal Isolates from Wounds and Nares of Diabetic Foot Patients Living in Erbil City, Iraq.

Current diabetes reviews·2026
Same author

Disinfectant/antiseptic resistance genes of Staphylococci and serotyping of clinical Staphylococcus aureus isolates.

Journal of infection in developing countries·2026
Same author

Examination of Genetic Mutations of Clofazimine Resistance in Drug-Resistant Mycobacterium TB Isolates.

Current microbiology·2025
Same author

Association of TOLLIP mRNA Expression and TOLLIP rs5743899A/G, TOLLIP rs3750920C/T, and IL-10 -1082G/A Single-Nucleotide Polymorphisms with Susceptibility to Tuberculosis.

Current microbiology·2025
Same author

Transcriptome-Based Analysis of the Oxidative Response of <i>Thermotoga maritima</i> to the O<sub>2</sub> Stress.

Combinatorial chemistry & high throughput screening·2025
Same author

[Examination of Capsule Genotypes, Antibiotic Susceptibility Profiles and Biofilm Forming Abilities of Group B Streptococcus Isolates Isolated from Pregnant Women].

Mikrobiyoloji bulteni·2025

Related Experiment Video

Updated: Dec 8, 2025

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
06:14

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients

Published on: October 15, 2017

8.6K

Efflux pump inhibitors: new updates.

Manaf AlMatar1, Osman Albarri2, Essam A Makky3

  • 1Faculty of Industrial Sciences and Technology, Universiti Malaysia Pahang (UMP), 26300, Gambang, Kuantan, Malaysia. manafmatar19@gmail.com.

Pharmacological Reports : PR
|September 18, 2020
PubMed
Summary

Bacterial resistance to antibiotics is a growing problem. This review explores efflux pumps, which help bacteria resist antibiotics and form biofilms, and discusses efflux pump inhibitors (EPIs) as a potential solution.

Keywords:
Antimicrobial resistanceBacterial infectionBiofilmEfflux pump inhibitors

More Related Videos

In vitro Investigation of the MexAB Efflux Pump From Pseudomonas aeruginosa
13:40

In vitro Investigation of the MexAB Efflux Pump From Pseudomonas aeruginosa

Published on: February 17, 2014

12.1K
Visualization of Bacterial Resistance using Fluorescent Antibiotic Probes
08:23

Visualization of Bacterial Resistance using Fluorescent Antibiotic Probes

Published on: March 2, 2020

13.3K

Related Experiment Videos

Last Updated: Dec 8, 2025

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
06:14

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients

Published on: October 15, 2017

8.6K
In vitro Investigation of the MexAB Efflux Pump From Pseudomonas aeruginosa
13:40

In vitro Investigation of the MexAB Efflux Pump From Pseudomonas aeruginosa

Published on: February 17, 2014

12.1K
Visualization of Bacterial Resistance using Fluorescent Antibiotic Probes
08:23

Visualization of Bacterial Resistance using Fluorescent Antibiotic Probes

Published on: March 2, 2020

13.3K

Area of Science:

  • Microbiology
  • Pharmacology
  • Biochemistry

Background:

  • Antibiotic resistance is a significant global health threat, driven by bacterial evolution.
  • Efflux pumps are key mechanisms bacteria use to expel antibiotics, contributing to treatment failure.
  • Efflux pumps are increasingly implicated in bacterial biofilm formation, complicating infections.

Purpose of the Study:

  • To review recent advancements in efflux pump inhibitors (EPIs).
  • To discuss the role of efflux pumps in bacterial biofilm development.
  • To explore strategies for combating biofilm-based infections by targeting efflux pumps.

Main Methods:

  • Literature review of studies on bacterial efflux pumps and biofilm formation.
  • Analysis of research on efflux pump inhibitors (EPIs) and their therapeutic potential.
  • Synthesis of evidence linking efflux pump activity to biofilm development and antibiotic resistance.

Main Results:

  • Efflux pumps significantly contribute to multidrug resistance in bacteria.
  • Evidence suggests a strong correlation between efflux pump activity and biofilm formation.
  • EPIs show promise in restoring antibiotic efficacy against resistant bacteria and preventing biofilms.

Conclusions:

  • Targeting efflux pumps with EPIs offers a promising strategy to overcome antibiotic resistance.
  • Understanding efflux pump involvement in biofilms is crucial for developing novel anti-biofilm agents.
  • Combined approaches targeting efflux pumps and biofilms could enhance treatment outcomes for bacterial infections.